-
1 month ago | 
urologytimes.com | David Braun |Hannah Clarke
In this interview, David A. Braun, MD, PhD, shares in-depth insights into the study, “Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC),” which was presented at the 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium in San Francisco, California. Braun is an assistant professor of medicine at Yale Cancer Center in New Haven, Connecticut. This transcript was AI generated and edited by human editors for clarity.
-
Oct 31, 2024 | 
onclive.com | David Braun
David A. Braun, MD, PhD, assistant professor, medical oncology, Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center, discusses advancements in biomarker development that could help guide treatment decision-making in patients with renal cell carcinoma (RCC).
-
Oct 25, 2024 | 
newswise.com | David Braun
David Braun, MD, PhD, assistant professor of medicine (medical oncology) at Yale School of Medicine and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center, will receive the Christopher G. Wood Rising Star Award by the Kidney Cancer Association at the 2024 International Kidney Cancer Symposium next month in Louisville, KY. He will be given the award at a ceremony during the symposium, which takes place between November 7 and 9.
-
Oct 14, 2024 | 
securityboulevard.com | Jeffrey Burt |David Braun
By Jeffrey Burt,David Braun The DOJ created NexFundAI, a false cryptocurrency company and token, in a sting that nabbed 19 people and companies accused of scamming investors by falsely creating the illusion of activity around their ...
-
Oct 7, 2024 | 
targetedonc.com | David Braun
Biomarkers play a crucial role in the management of renal cell carcinoma (RCC). These biological molecules can provide valuable information about the disease's progression, prognosis, and potential response to treatment. For the oncologist, biomarkers play an important role in treatment planning, prognosis, treatment selection, and monitoring disease progression. With advances in research identifying novel biomarkers.
-
Oct 5, 2024 | 
targetedonc.com | David Braun
The CheckMate 9ER study (NCT03141177) investigated the role of protein glycosylation as predictive and prognostic biomarkers for response to nivolumab (Opdivo) and cabozantinib (Cabometyx) or sunitinib (Sutent) in patients with advanced renal cell carcinoma (aRCC). A novel glycoproteomic platform was used to analyze serum samples from 189 patients treated with nivolumab/cabozantinib or sunitinib in the CheckMate 9ER trial.
-
Sep 23, 2024 | 
urotoday.com | David Braun
Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here today with Dr. David Braun, who is joining me after ESMO 2024, where he presented some really fascinating work in the CheckMate 9ER study in kidney cancer. Thank you so much for being here today, Dr. Braun, and please tell us a little bit about it. David Braun: Absolutely. Very happy to do so, and thank you so much for having me on today.
-
Sep 11, 2024 | 
onclive.com | David Braun
David A. Braun, MD, PhD, assistant professor, medical oncology, Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center, discusses the role of biomarkers in optimizing adjuvant treatment strategies for renal cell carcinoma (RCC). Although biomarkers are commonly thought of as factors to help guide treatment in the metastatic setting, Braun explains the need for their integration in the adjuvant setting to better guide treatment decisions.
-
Sep 2, 2024 | 02563-6/fulltext?rss=yes&sz=64)
europeanurology.com | Sandy Figiel |Anthony Bates |David Braun |Renu S. Eapen |Markus Eckstein |Brandon Manley | +5 more
KeywordsGenomicsTranscriptomicsProteomicsUrological cancer1 IntroductionAlbert Einstein famously said: “Look deep into nature, and then you will understand everything better”, and although he wrote this 2 yr before Francis Crick and James Watson [1]1. Watson, J.D. ∙ Crick, F.H.C.Molecular structure of nucleic acids: a structure for deoxyribose nucleic acidNature. 1953; 171:737-738 discovered DNA, he may well have had genes in mind.
-
Aug 16, 2024 | 
onclive.com | David Braun
CommentaryVideoAugust 16, 2024Author(s):Fact checked by:David A. Braun, MD, PhD, discusses the variety of therapies available for the treatment of patients with kidney cancer. David A.
